louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00993525: Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
Official title: INTRAVITREAL RANIBIZUMAB FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (INIPE STUDY)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Proliferative Diabetic Retinopathy
Keywords: diabetic retinopathy
ranibizumab
new vessels
intravitreal injection
Persistent retina new vessels
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
Collaborators: name: Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP (FAEPA)
name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2009-10-12
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.


Eligibility criteria: Inclusion Criteria:

* persistent new vessels,defined as fine retinal vessels with dilated buds or tips covered with hemorrhage or associated with recurrent vitreous hemorrhage or paucity of accompanying fibrous tissue and/or increased in extent compared to previous visit,unresponsive to complete panretinal laser photocoagulation performed at least 4 months prior;
* logarithm of minimum angle of resolution (logMAR) best-corrected visual acuity of 0.17 (Snellen equivalent, 20/30) or worse.

Exclusion Criteria:

* history of vitrectomy in the study eye;
* history of thromboembolic event (including myocardial infarction or cerebral vascular accident);
* major surgery within the prior 6 months or planned within the next 28 days;
* uncontrolled hypertension;
* known coagulation abnormalities or current use of anticoagulative medication other than aspirin.

Primary outcomes:
measure: total area of fluorescein leakage from active new vessels
timeFrame: baseline, weeks 1,6,12,24,36,48
measure: Best corrected Visual Acuity (BCVA)
timeFrame: Baseline, weeks 1,6,12,24,36,48
measure: central macular thickness
timeFrame: baseline, weeks 1,6,12,24,36,48
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Sao Paulo
name: Rodrigo Jorge, MD
role: STUDY_CHAIR
References:
citation: Messias A, Ramos Filho JA, Messias K, Almeida FP, Costa RA, Scott IU, Gekeler F, Jorge R. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy. Doc Ophthalmol. 2012 Jun;124(3):225-36. doi: 10.1007/s10633-012-9322-5. Epub 2012 Mar 29.
Clinical trial NCT06448325: Fragility Re-fractures Prediction Score
Official title: RIFRA - Re-fracture Risk Prediction in Patients With Fragility Fracture: Score Development and Validation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Osteoporosis Risk
Lead sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Sponsor class: OTHER
First posted: 2024-06-07
Enrollment: 800
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients aged 60 or more, of all sexes.

Brief summary: Fragility fractures increase among elderly patients worldwide, representing a global burden in terms of disability and care expenditure.

Osteoporosis is asymptomatic up to the moment in which a first fracture occurs, reason why it is often underdiagnosed. Even after that, further fractures do occurr, as osteoporosis is often untreated. Several programs have been introduced worldwide to prevent secondary fractures among the population at risk (e.g., International Osteoporosis Foundation's Capture the Fracture), and several risk factors are being investigated to generate a predictive score. However, accurate validation is needed to make these scores reliable.

In this retrospective observational study, we aim to validate a predictive score trained on a population of elderly patients with a cohort of patients who underwent hip fracture surgery in a high-volume orthopedic center in the Region of Lombardy.


Eligibility criteria: Inclusion Criteria:

* People who underwent total or partial hip replacement (ICD 9 CM 81.51, 81.52) in five years (2013-2017) at the hospital for a compound fracture of the hip (ICD 9 CM 820, 820.01-820.09).

Exclusion Criteria:

* People undergoing the same intervention for other reasons (e.g. pathological fracture, ICD 9 CM 733.14).

ICD 9 CM stands for International Classification of Disease, 9th Revision, Clinical Modification.

Primary outcomes:
measure: Age, sex, disease name and body mass index (weight in kg and height in m will be combined to report BMI in kg/m^2)
timeFrame: Baseline: the outcomes are assessed before surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS Ospedale Galeazzi-Sant'Ambrogio
state: Italia
Study officials:
References:
Clinical trial NCT03388125: Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection
Official title: Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Bleeding Esophageal Varices
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2018-01-02
Enrollment: 113
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Detailed description: Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Eligibility criteria: Inclusion Criteria:

* cirrhotic patients presented with actively bleeding

Exclusion Criteria:

* other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)

Primary outcomes:
measure: Number of patients with controlled bleeding
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Sherief Abd-Elsalam
Study officials:
affiliation: Gastroenterology
name: Mohamed Alsebaey, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Gastroenterology
name: Mohamed Abdelraouf, MD
role: STUDY_DIRECTOR
affiliation: Hepatology and Gastroenterology
name: Sherief Abd-Elsalam, MD
role: STUDY_DIRECTOR
References:
citation: Elsebaey MA, Tawfik MA, Ezzat S, Selim A, Elashry H, Abd-Elsalam S. Endoscopic injection sclerotherapy versus N-Butyl-2 Cyanoacrylate injection in the management of actively bleeding esophageal varices: a randomized controlled trial. BMC Gastroenterol. 2019 Feb 4;19(1):23. doi: 10.1186/s12876-019-0940-1.
Clinical trial NCT02164825: Total Knee Arthroplasty Analgesia: Single-shot Femoral Nerve Block or Epidural?
Official title: Comparison Between Single-shot Femoral Nerve Block and Epidural Techniques for Total Knee Arthroplasty: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain Treatment for Total Knee Arthroplasty
Lead sponsor: Centro Hospitalar do Tâmega e Sousa
Sponsor class: OTHER
First posted: 2014-06-17
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Single-shot femoral nerve block is similar to continuous epidural technique for postoperative analgesia in total knee arthroplasty


Eligibility criteria: Inclusion Criteria:

* Elective total knee arthroplasty

Exclusion Criteria:

* Coagulopathy
* Neuropathy
* Morbid obesity
* local anesthetics allergy

Primary outcomes:
measure: Pain Score on the numeric pain score
timeFrame: 48 hours
Secondary outcomes:
measure: Side effects as a measure of safety and tolerability
timeFrame: 48 hours
measure: Rescue analgesic consumption.
timeFrame: 48 hours
measure: Patients satisfaction.
timeFrame: 48 hours
Other outcomes:
Locations:
city: Penafiel
country: Portugal
facility: Centro Hospitalar Tâmega e Sousa
Study officials:
References:
Clinical trial NCT00038025: A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
Official title: A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Peripheral T-cell Lymphoma
Cutaneous T-cell Lymphoma
Chronic Lymphocytic Leukemia
Keywords: Mycosis Fungoides
Lymphoma
Chronic lymphocytic leukemia
Deoxycoformycin
Pentostatin
All other lymphomas
Nucleoside analogue
Adenosine deaminase inhibitor
T-cells
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2002-05-27
Enrollment: 60
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.

Detailed description: Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed.

Eligibility criteria: Inclusion Criteria:

* Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy.
* No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy.
* Life expectancy of at least 12 weeks.
* Performance status equal to or less than Zubrod 2.
* Signed informed consent.
* Patients with measurable disease.
* Age at least 16 years.
* Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000.
* Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal.
* Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.

Exclusion Criteria:

* No serious intercurrent illness.
* Adequate contraception (if applicable).
* NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV.
* NO experimental clinical trial within 3 weeks of study entry.
* NO patients with active CNS disease.
* Full recovery from any prior surgical treatment.
* NO active active infections.

Primary outcomes:
measure: Number of Participants with Overall Response
timeFrame: Baseline and approximately every 3 weeks thereafter
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: M. D. Anderson Cancer Center
state: Texas
Study officials:
affiliation: MD Anderson
name: Razelle Kurzrock, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03438825: PRediction of Early PostoperAtive Right vEntricular Failure in Mitral Valve Replacement/Repair Patients
Official title: The PREPARE-MVR Study: PRediction of Early PostoperAtive Right vEntricular Failure in Mitral Valve Replacement/Repair Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Right Heart Failure
Right Ventricular Dysfunction
Right Ventricular Failure
Mitral Valve Disease
Lead sponsor: Semmelweis University Heart and Vascular Center
Sponsor class: OTHER
First posted: 2018-02-20
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with isolated severe mitral valve insufficiency admitted for replacement/repair surgery as described in inclusion, exclusion criteria

Brief summary: The PREPARE-MVR (PRediction of Early PostoperAtive Right vEntricular failure in Mitral Valve Replacement/Repair patients) Study aims to evaluate those preoperative factors which can predict the early postoperative right ventricular failure or determine the functional shift seen in right ventricular function after mitral valve replacement/repair. The PREPARE-MVR study focuses mainly on echocardiographic (both conventional and advanced) parameters and includes right heart catheterization intraoperatively and in the early postoperative period as gold standard method.


Eligibility criteria: Inclusion Criteria:

* patients admitted for mitral valve replacement/repair
* severe mitral valve insufficiency

Exclusion Criteria:

* preoperative right ventricular dysfunction
* cardiac surgery in medical history
* infective endocarditis
* primary cardiomyopathies
* congenital heart disease
* decreased left ventricular ejection fraction
* pulmonary embolism in medical history
* severe chronic obstructive pulmonary disease
* primary pulmonary hypertension
* any malignancy affecting right heart

Primary outcomes:
measure: right ventricular failure
timeFrame: From date of operation until the date of first documented right ventricular failure assessed up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Budapest
country: Hungary
facility: Semmelweis University Heart and Vascular Center
Study officials:
References:
citation: Tokodi M, Nemeth E, Lakatos BK, Kispal E, Toser Z, Staub L, Racz K, Soltesz A, Szigeti S, Varga T, Gal J, Merkely B, Kovacs A. Right ventricular mechanical pattern in patients undergoing mitral valve surgery: a predictor of post-operative dysfunction? ESC Heart Fail. 2020 Jun;7(3):1246-1256. doi: 10.1002/ehf2.12682. Epub 2020 Mar 26.
Clinical trial NCT00187525: A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Frontotemporal Lobar Degeneration
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Forest Laboratories
First posted: 2005-09-16
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.


Eligibility criteria: Inclusion Criteria:

* Neary et al. Criteria for Frontotemporal Lobar Degeneration
* Age 40 -80
* CDR \< 3 or MMSE \> 15
* English Speaking
* Study Partner

Exclusion Criteria:

* Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Boxer AL, Lipton AM, Womack K, Merrilees J, Neuhaus J, Pavlic D, Gandhi A, Red D, Martin-Cook K, Svetlik D, Miller BL. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):211-7. doi: 10.1097/WAD.0b013e318197852f.
Clinical trial NCT00889525: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Official title: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Cushing's Disease
Corticotroph Adenoma
Keywords: Cabergoline
Lead sponsor: Seth Gordhandas Sunderdas Medical College
Sponsor class: OTHER
First posted: 2009-04-29
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.

Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.


Eligibility criteria: Inclusion Criteria:

* Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology

Exclusion Criteria:

* Patient's intolerance to drug or known sensitivity to ergot derivatives
* Pregnancy, lactation or female wishing to be pregnant
* Any serious medical illness
* Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc

Primary outcomes:
measure: Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl
Secondary outcomes:
Other outcomes:
Locations:
city: Mumbai
country: India
facility: Seth GSMC & KEM hospital
state: Maharashtra
Study officials:
affiliation: Seth GSMC and KEM hospital, Mumbai
name: Nalini S Shah, DM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06937125: Evaluation of Valvular Heart Disease Using Cardiac CT
Official title: Evaluation of Valvular Heart Disease: Multicenter Registry of Noninvasive Imaging Modalities by Cardiac CT
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Valvular Heart Disease
Lead sponsor: Toho University
Sponsor class: OTHER
First posted: 2025-04-22
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will be conducted at 7 centers throughout Japan, with the goal of enrolling a total of approximately 300-350 cases.

Brief summary: The EVIDENTIA Registry is a multicenter study designed to evaluate valvular heart disease (VHD) using cardiac CT. It aims to assess cardiac valve anatomy, function, and myocardial characteristics through detailed CT analysis.

1. Assessing the accuracy of cardiac CT in evaluating cardiac structure, volume, function, and myocardium in VHD patients.
2. Comparing the severity, classification, and etiology (primary vs. functional) of VHD.
3. Monitoring serial changes in VHD severity via echocardiography.
4. Investigating the relationship between echocardiographic and CT-derived parameters.
5. Examining the correlation between imaging findings, VHD interventions, and patient prognosis.


Eligibility criteria: Inclusion Criteria:

* Patients with at least moderate valvular heart disease who had a cardiac CT with 64 or more rows
* 18 years of age or older

Exclusion Criteria:

* Less than 18 years old
* Acute VHD
* Infectious endocarditis
* Patients with post-VHD intervention
* Poor CT image quality for analyzing CT data.

Primary outcomes:
measure: the 1-year composite endpoint of all-cause death and major cardiac adverse events (MACE) including VHD intervention.
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Ota
country: Japan
facility: Toho University
state: Tokyo
Study officials:
References:
Clinical trial NCT02261025: The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis
Official title: The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemodialysis
Keywords: aspirin
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2014-10-09
Enrollment: 410
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of present study is to examine the effect of low-dose aspirin on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis.

Detailed description: This study prospectively evaluate the impacts of low dose aspirin on survival and cardio-cerebral vascular events in a large cohort of Chinese patients undergoing chronic hemodialysis. Between January 2008, consecutive patients with hemodialysis with aspirin were enrolled.We examine the association of aspirin with all-cause mortality in patients matched by propensity scores using the Kaplan-Meier method and Cox models in "intention-to-treat" analyses.The secondary endpoint was rate of cardio-cerebral events.

Eligibility criteria: Inclusion Criteria:

All patients aged 18 to 85, undergoing chronic hemodialysis, who have none of the following exclusion criteria.

Exclusion Criteria:

History of gastric or duodenal ulcers Known allergy to aspirin or other NSAIDs

-

Primary outcomes:
measure: survival rate
timeFrame: 5 years
Secondary outcomes:
measure: cardio-cerebral event
timeFrame: 5 years
Other outcomes:
Locations:
Study officials:
References:
citation: Liu J, Pan Y, Chen L, Qiao QY, Wang J, Pan LH, Gu YH, Gu HF, Fu SK, Jin HM. Low-dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: A 5-y prospective cohort study. Hemodial Int. 2016 Oct;20(4):548-557. doi: 10.1111/hdi.12409. Epub 2016 Mar 1.
Clinical trial NCT04448925: Physiological Responses to Maximal 4-s Sprint Interval Cycling
Official title: Physiological Responses to Maximal 4-s Sprint Interval Cycling Using Inertial Loading: the Influence of Inter-sprint Recovery Duration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise, Cardiovascular Function, Fatigue, Muscular Power
Lead sponsor: University of Texas at Austin
Sponsor class: OTHER
First posted: 2020-06-26
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Repeated measures, cross-over
Primary purpose: BASIC_SCIENCE

Brief summary: The optimal recovery duration depends on the intensity of exercise and in the present study the intensity was maximal power for 4-s while cycling an 'Inertial Load' ergometer (ILE). Recovery duration of 15, 30 and 45-s were given between 30 successive sprints.

Detailed description: All subjects completed an informed consent for this study that was approved by the Institutional Review Board of the University of Texas at Austin.

Study Overview. A randomized, cross-over experimental design was conducted. Each participant visited the laboratory on four occasions which were separated by two to five days. Measurement of body mass, familiarization with experimental procedures and cycling peak oxygen consumption test (VO2peak) were performed on the first visit. Participants took part in inertial-load exercise (ILE) on the remaining test days. On each separate session, a different inter-sprint recovery duration was employed (i.e. 15, 30 or 45-s). Cycling power output, pulmonary gas exchange, vastus lateralis de-oxygenation status, heart rate and blood lactate were measured.

Eligibility criteria: Inclusion Criteria:

* healthy participants

Exclusion Criteria:

* unhealthy

Primary outcomes:
measure: maximal leg power
timeFrame: 10 min
Secondary outcomes:
Other outcomes:
Locations:
city: Austin
country: United States
facility: University of Texas at Austin Human Performance Laboratory
state: Texas
Study officials:
References:
citation: Vardarli E, Satiroglu R, Allen JR, Bjellquist-Ledger R, Burton HM, Coyle EF. Physiological responses to maximal 4 s sprint interval cycling using inertial loading: the influence of inter-sprint recovery duration. Eur J Appl Physiol. 2021 Aug;121(8):2295-2304. doi: 10.1007/s00421-021-04677-6. Epub 2021 May 11.